SAR439977
Total Payments
$14.3M
Transactions
5,272
Doctors
76
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $9.1M | 1,362 | 10 |
| 2018 | $4.0M | 3,471 | 68 |
| 2017 | $1.2M | 439 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.3M | 5,197 | 99.6% |
| Consulting Fee | $41,475 | 12 | 0.3% |
| Travel and Lodging | $19,497 | 54 | 0.1% |
| Food and Beverage | $1,460 | 9 | 0.0% |
Payments by Type
Research
$14.3M
5,197 transactions
General
$62,432
75 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular | SANOFI US SERVICES INC. | $3.5M | 40 |
| A 56-week, Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly Compared to Dulaglutide Once Weekly in Patients With Type 2 Dia | SANOFI US SERVICES INC. | $2.9M | 20 |
| A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr | SANOFI US SERVICES INC. | $2.3M | 1 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have | SANOFI US SERVICES INC. | $1.9M | 0 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk | SANOFI US SERVICES INC. | $1.6M | 5 |
| A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr | SANOFI US SERVICES INC. | $1.2M | 1 |
| Eff-naive vs pcbo | SANOFI US SERVICES INC. | $786,922 | 0 |
| A 30-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Contr | SANOFI US SERVICES INC. | $64,716 | 0 |
| A 30-week, multicenter, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of efpeglenatide once weekly in patients with Type 2 diabetes mellitus inadequately contr | SANOFI US SERVICES INC. | $3,500 | 0 |
| A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control | SANOFI US SERVICES INC. | $900.00 | 0 |
Top Doctors Receiving Payments for SAR439977
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Research Triangle Park, NC | $13.8M | 4,760 |
| , D.O | Internal Medicine | Pembroke Pines, FL | $188,815 | 5 |
| , M.D | Family Medicine | Gilbert, AZ | $70,376 | 13 |
| , M.D | Cardiovascular Disease | Nashville, TN | $58,824 | 17 |
| , MD | Surgery | Oxon Hill, MD | $53,452 | 17 |
| , MD | Family Medicine | Richmond, TX | $21,693 | 15 |
| , M.D | Internal Medicine | San Antonio, TX | $18,244 | 4 |
| , MD | Internal Medicine | Norfolk, VA | $14,026 | 8 |
| , M.D | Endocrinology, Diabetes & Metabolism | Dallas, TX | $10,812 | 5 |
| , MD | Ophthalmology | Chicago, IL | $10,676 | 7 |
| , M.D | Endocrinology, Diabetes & Metabolism | Los Gatos, CA | $10,096 | 6 |
| , M.D | Endocrinology, Diabetes & Metabolism | San Diego, CA | $8,261 | 9 |
| , MD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $7,838 | 3 |
| , M.D | Endocrinology, Diabetes & Metabolism | Greenville, NC | $5,752 | 7 |
| , MD, MMSC | Internal Medicine | Skokie, IL | $5,585 | 7 |
| , D.O | Family Medicine | Charleston, SC | $4,352 | 8 |
| , MD | Internal Medicine | Pomona, CA | $3,234 | 12 |
| , M.D | Internal Medicine | Maumee, OH | $2,906 | 7 |
| , MD | Internal Medicine | Bridgeton, NJ | $2,780 | 7 |
| , MD | Endocrinology, Diabetes & Metabolism | Morehead City, NC | $2,139 | 13 |
| , M.D | Internal Medicine | Burke, VA | $2,076 | 4 |
| , D.C | Chiropractor | Los Angeles, CA | $2,004 | 4 |
| , DO | Family Medicine | Spring Valley, CA | $1,969 | 4 |
| , MD | Family Medicine | Tucson, AZ | $1,930 | 4 |
| , M.D | Internal Medicine | Birmingham, AL | $1,840 | 4 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $14.3M
- SANOFI-AVENTIS U.S. LLC $50,245
Product Information
- Type Drug
- Total Payments $14.3M
- Total Doctors 76
- Transactions 5,272
About SAR439977
SAR439977 is a drug associated with $14.3M in payments to 76 healthcare providers, recorded across 5,272 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $9.1M was paid across 1,362 transactions to 10 doctors.
The most common payment nature for SAR439977 is "Unspecified" ($14.3M, 99.6% of total).
SAR439977 is associated with 10 research studies, including "A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular" ($3.5M).